Zobrazeno 1 - 10
of 392
pro vyhledávání: '"Y. Janjigian"'
Autor:
Yonina R. Murciano-Goroff, Alison M. Schram, Ezra Y. Rosen, Helen Won, Yixiao Gong, Anne Marie Noronha, Yelena Y. Janjigian, Zsofia K. Stadler, Jason C. Chang, Soo-Ryum Yang, Diana Mandelker, Kenneth Offit, Michael F. Berger, Mark T. A. Donoghue, Chaitanya Bandlamudi, Alexander Drilon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
Mutations in BRCA1/2 are associated with a homologous recombination deficiency phenotype in BRCA-associated cancers. Reversion mutations can restore BRCA1/2 function and result in treatment resistance in these cancer-types. Here, the authors show tha
Externí odkaz:
https://doaj.org/article/c02201f79842463bb00562d13b866e18
Autor:
Patrícia M. R. Pereira, Komal Mandleywala, Sébastien Monette, Melissa Lumish, Kathryn M. Tully, Sandeep Surendra Panikar, Mike Cornejo, Audrey Mauguen, Ashwin Ragupathi, Nai C. Keltee, Marissa Mattar, Yelena Y. Janjigian, Jason S. Lewis
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-14 (2022)
Clinical evidences have demonstrated limited efficacy of HER2-targeted therapies in patients with gastric cancer (GC). Here the authors show that survival benefit to anti-HER2 antibody Trastuzumab is reduced in GC patients with high levels of the cav
Externí odkaz:
https://doaj.org/article/38bd18f4fd924b1c8813870074036bf4
Autor:
Brendan John Guercio, Gopa Iyer, Wajih Zaheer Kidwai, Mario E. Lacouture, Soleen Ghafoor, Anthony M. Rossi, David N. Assis, Ying-Bei Chen, Klaus J. Busam, Yelena Y. Janjigian, Komal Jhaveri, Darren R. Feldman, Anne Capozzi, Vanessa Figueroa, Dean F. Bajorin, Jonathan E. Rosenberg, Travis J. Hollmann, Samuel A. Funt
Publikováno v:
Case Reports in Oncology, Vol 14, Iss 1, Pp 430-438 (2021)
Metastatic primary cutaneous extramammary Paget disease (EMPD) is a rare clinical entity with a 5-year survival
Externí odkaz:
https://doaj.org/article/d76cb10bfe2348a4802b4d6e377656f7
Autor:
Smita Sihag, Geoffrey Y. Ku, Kay See Tan, Abraham J. Wu, Yelena Y. Janjigian, Steven Brad Maron, David R. Jones, Laura H. Tang, Daniela Molena, Tamar B. Nobel, Manjit S. Bains, Sergio De La Torre, Meier Hsu
Publikováno v:
Ann Surg
OBJECTIVE: To evaluate whether pathologic complete response (pCR) exclusively defines major pathologic response to treatment with improved survival. SUMMARY BACKGROUND DATA: pCR following trimodality therapy for esophagogastric adenocarcinoma is infr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::919e67777e51a786bb96f65c7b100615
https://pubmed.ncbi.nlm.nih.gov/33214465
https://pubmed.ncbi.nlm.nih.gov/33214465
Autor:
Patrícia M. R. Pereira, Sai Kiran Sharma, Lukas M. Carter, Kimberly J. Edwards, Jacob Pourat, Ashwin Ragupathi, Yelena Y. Janjigian, Jeremy C. Durack, Jason S. Lewis
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Trastuzumab binding to tumor cells depends on the availability of HER2 at the cell membrane. Here the authors show that caveolin-1 (CAV1) regulates HER2 density at the cell membranes and that CAV1 gene knockdown or protein depletion via the cholester
Externí odkaz:
https://doaj.org/article/655bc247cda34be5801b730bd0910363
Autor:
Samuel L. Cytryn, Yelena Y. Janjigian
Publikováno v:
Journal of the National Comprehensive Cancer Network. 21:423-429
HER2 is overexpressed in approximately 20% of esophagogastric cancer (EGC) cases. The addition of the anti-HER2 antibody, trastuzumab, to chemotherapy in 2010 was the first targeted treatment to demonstrate an improvement in survival. The aggressive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c297f4d03c6d47c3bbdd0caa0c72c1f
https://doi.org/10.6004/jnccn.2023.7010
https://doi.org/10.6004/jnccn.2023.7010
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Esophagogastric cancer (EGC) remains a major cause of cancer-related mortality. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to-date: only firs
Externí odkaz:
https://doaj.org/article/d6715a335f934cd9b420ce3bf5e3f9c1
Autor:
Miseker Abate, Elvira Vos, Mithat Gonen, Yelena Y. Janjigian, Mark Schattner, Monika Laszkowska, Laura Tang, Steven B. Maron, Daniel G. Coit, Santosh Vardhana, Chad Vanderbilt, Vivian E. Strong
Publikováno v:
Annals of surgery. 276(4)
The microbiome is hypothesized to have a significant impact on cancer development. In gastric cancer (GC), Helicobacter pylori is an established class I carcinogen. However, additional organisms in the intratumoral microbiome play an important role i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07e4233500aa690eb6d8fa308c1afda9
https://pubmed.ncbi.nlm.nih.gov/35822725
https://pubmed.ncbi.nlm.nih.gov/35822725
Autor:
Thomas Boerner, Caitlin Harrington, Kay See Tan, Prasad S. Adusumilli, Manjit S. Bains, Matthew J. Bott, Robert J. Downey, James Huang, David H. Ilson, James M. Isbell, Yelena Y. Janjigian, Bernard J. Park, Gaetano Rocco, Valerie W. Rusch, Smita Sihag, Abraham J. Wu, David R. Jones, Daniela Molena
Publikováno v:
Annals of Surgery. 277:781-788
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10e251053c3ddd07edf71c93c409cfc0
https://doi.org/10.1097/sla.0000000000005798
https://doi.org/10.1097/sla.0000000000005798
Autor:
Zev A. Wainberg, Jipan Xie, Adriana Valderrama, Lei Yin, Shujing Zhang, Chie-Schin Shih, Pooja Bhagia, Qianqian Gu, Kohei Shitara, Yelena Y. Janjigian, Josep Tabernero
Publikováno v:
Clinical Cancer Research. 29:1360-1367
Purpose: This study assessed the trial-level association between event-free survival (EFS) and overall survival (OS) in gastric or gastroesophageal junction (GEJ) adenocarcinoma in the neoadjuvant ± adjuvant settings. Experimental Design: A systemat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c39e4f987dfde3d5dce990ec84d81553
https://doi.org/10.1158/1078-0432.ccr-22-2920
https://doi.org/10.1158/1078-0432.ccr-22-2920